

# Viet Nam

## Tuberculosis profile

Population 2018

96 million

Estimates of TB burden <sup>o</sup> , 2018	Number (thousands)	Rate (per 100 000 population)
Total TB incidence	174 (111–251)	182 (116–263)
HIV-positive TB incidence	6 (3.8–8.6)	6.2 (4–9)
MDR/RR-TB incidence <sup>oo</sup>	8.6 (5.4–13)	9.1 (5.7–13)
HIV-negative TB mortality	11 (6.7–15)	11 (7–16)
HIV-positive TB mortality	2.2 (1.4–3.2)	2.3 (1.5–3.4)

### Estimated proportion of TB cases with MDR/RR-TB, 2018

New cases	3.6% (3.4–3.8)
Previously treated cases	17% (17–18)

### TB case notifications, 2018

Total new and relapse	99 658
- % tested with rapid diagnostics at time of diagnosis	20%
- % with known HIV status	85%
- % pulmonary	80%
- % bacteriologically confirmed <sup>ooo</sup>	70%
- % children aged 0-14 years	2%
- % women	27%
- % men	71%
Total cases notified	102 171

### Universal health coverage and social protection

TB treatment coverage (notified/estimated incidence), 2018	57% (40–90)
TB patients facing catastrophic total costs, 2016	63% (58–67)
TB case fatality ratio (estimated mortality/estimated incidence), 2018	8% (4–12)

### TB/HIV care in new and relapse TB patients, 2018

	Number	(%)
Patients with known HIV status who are HIV-positive	2 902	3%
- on antiretroviral therapy	2 705	93%

### Drug-resistant TB care, 2018

% of bacteriologically confirmed TB cases tested for rifampicin resistance <sup>ooo</sup>	
- New cases	82%
- Previously treated cases	100%
Laboratory-confirmed cases*	MDR/RR-TB: 3 126, XDR-TB: 61
Patients started on treatment**	MDR/RR-TB: 3 110, XDR-TB: 198
MDR/RR-TB cases tested for resistance to second-line drugs	1 922

### Treatment success rate and cohort size

	Success	Cohort
New and relapse cases registered in 2017	92%	102 193
Previously treated cases, excluding relapse, registered in 2017	87%	2 983
HIV-positive TB cases registered in 2017	79%	3 002
MDR/RR-TB cases started on second-line treatment in 2016	68%	2 450
XDR-TB cases started on second-line treatment in 2016	68%	28

### TB preventive treatment, 2018

% of HIV-positive people (newly enrolled in care) on preventive treatment	39%
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment	22% (21–25)

### TB financing, 2019

National TB budget (US\$ millions)	72
Funding source: 14% domestic, 24% international, 62% unfunded	

<sup>o</sup> Ranges represent uncertainty intervals


<sup>oo</sup> MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

<sup>ooo</sup> Calculated for pulmonary cases only

\* Includes cases with unknown previous TB treatment history


\*\* Includes patients diagnosed before 2018 and patients who were not laboratory-confirmed

(Rate per 100 000 population per year)




Legend:  
■ Total TB incidence  
■ New and relapse TB cases notified  
■ HIV-positive TB incidence

(Rate per 100 000 population per year)




Legend:  
■ HIV-negative TB mortality

### Notified cases by age group and sex, 2018




Legend:  
■ Females ■ Males  Incidence

Treatment success rate (%)



Legend:  
■ New and relapse  
■ Retreatment, excluding relapse  
■ HIV-positive ■ MDR/RR-TB ■ XDR-TB

Total budget (US\$ millions)



Legend:  
■ Unfunded  
■ Funded internationally  
■ Funded domestically